Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
$1.93
+2.1%
$1.94
$1.12
$4.20
$143.48M0.92276,378 shs162,288 shs
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
$2.82
+1.4%
$2.00
$0.81
$3.11
$94.07M-0.09149,175 shs80,550 shs
Promis Neurosciences stock logo
PMN
Promis Neurosciences
$0.42
-2.4%
$0.51
$0.38
$2.37
$14.13M-0.181,671 shs150,609 shs
SBM
ProShares Short Basic Materials
$46.38
$46.38
$42.85
$55.15
$1.86MN/A3,024 shsN/A
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
$15.89
+1.4%
$14.11
$9.90
$27.20
$1.28B0.391.15 million shs935,231 shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
+2.12%-1.03%-1.53%+16.27%+66.38%
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-2.76%+9.73%+48.42%+163.55%+135.00%
Promis Neurosciences stock logo
PMN
Promis Neurosciences
-8.86%-12.77%-11.72%-30.76%-76.42%
SBM
ProShares Short Basic Materials
0.00%0.00%0.00%0.00%0.00%
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
+1.96%+13.66%+8.24%+44.19%+28.98%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
1.3227 of 5 stars
3.31.00.00.01.80.00.6
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
1.8292 of 5 stars
3.53.00.00.00.61.70.0
Promis Neurosciences stock logo
PMN
Promis Neurosciences
3.3585 of 5 stars
3.55.00.00.00.00.81.3
SBM
ProShares Short Basic Materials
N/AN/AN/AN/AN/AN/AN/AN/A
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
1.7623 of 5 stars
4.50.00.00.02.20.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
2.50
Moderate Buy$6.50236.79% Upside
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
3.00
Buy$7.00148.23% Upside
Promis Neurosciences stock logo
PMN
Promis Neurosciences
3.00
Buy$4.50966.35% Upside
SBM
ProShares Short Basic Materials
0.00
N/AN/AN/A
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
2.90
Moderate Buy$37.56136.35% Upside

Current Analyst Ratings Breakdown

Latest VRDN, SBM, IKT, PMN, and OKYO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
5/12/2025
Promis Neurosciences stock logo
PMN
Promis Neurosciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$3.00
5/7/2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$31.00 ➝ $27.00
5/7/2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$46.00 ➝ $45.00
5/7/2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$42.00 ➝ $38.00
5/7/2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$38.00 ➝ $36.00
5/5/2025
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
4/23/2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$34.00 ➝ $34.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/AN/AN/AN/A$1.78 per shareN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/A($0.20) per shareN/A
Promis Neurosciences stock logo
PMN
Promis Neurosciences
N/AN/AN/AN/A$0.50 per shareN/A
SBM
ProShares Short Basic Materials
N/AN/AN/AN/AN/AN/A
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
$300K4,321.55N/AN/A$6.09 per share2.61
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
-$16.83MN/A0.00N/AN/AN/AN/AN/A8/12/2025 (Estimated)
Promis Neurosciences stock logo
PMN
Promis Neurosciences
$2.78M-$0.05N/AN/AN/AN/A-186.19%-98.56%8/6/2025 (Estimated)
SBM
ProShares Short Basic Materials
N/AN/A0.00N/AN/AN/AN/AN/A
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
-$269.95M-$3.85N/AN/AN/A-102,092.39%-70.61%-44.67%8/14/2025 (Estimated)

Latest VRDN, SBM, IKT, PMN, and OKYO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Promis Neurosciences stock logo
PMN
Promis Neurosciences
-$0.14-$0.21-$0.07-$0.21N/AN/A
5/6/2025Q1 2025
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
-$0.95-$0.87+$0.08-$0.87$0.16 million$0.07 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/AN/AN/AN/AN/A
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/AN/AN/A
Promis Neurosciences stock logo
PMN
Promis Neurosciences
N/AN/AN/AN/AN/A
SBM
ProShares Short Basic Materials
N/A0.00%N/AN/AN/A
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/A
0.85
0.85
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
N/AN/AN/A
Promis Neurosciences stock logo
PMN
Promis Neurosciences
N/A
3.36
3.36
SBM
ProShares Short Basic Materials
N/AN/AN/A
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
0.05
19.49
19.49
CompanyEmployeesShares OutstandingFree FloatOptionable
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
674.34 million66.18 millionNot Optionable
OKYO Pharma Limited Sponsored ADR stock logo
OKYO
OKYO Pharma
733.84 million20.15 millionNot Optionable
Promis Neurosciences stock logo
PMN
Promis Neurosciences
532.69 million30.69 millionNot Optionable
SBM
ProShares Short Basic Materials
N/A40,000N/ANot Optionable
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
5081.59 million81.06 millionOptionable

Recent News About These Companies

Viridian Therapeutics: The Song Remains The Same
Viridian Therapeutics appoints Ajer to its board of directors

New MarketBeat Followers Over Time

Media Sentiment Over Time

Inhibikase Therapeutics stock logo

Inhibikase Therapeutics NYSE:IKT

$1.93 +0.04 (+2.12%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$1.93 0.00 (0.00%)
As of 07/7/2025 06:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

OKYO Pharma stock logo

OKYO Pharma NASDAQ:OKYO

$2.82 +0.04 (+1.44%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$2.92 +0.10 (+3.55%)
As of 07/7/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Promis Neurosciences stock logo

Promis Neurosciences NASDAQ:PMN

$0.42 -0.01 (-2.38%)
Closing price 07/7/2025 03:26 PM Eastern
Extended Trading
$0.39 -0.03 (-7.11%)
As of 07/7/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

ProShares Short Basic Materials NYSEARCA:SBM

$46.38 0.00 (0.00%)
As of 05/12/2023

ProShares Short Basic Materials (the Fund) seeks daily investment results that correspond to the inverse (opposite) of the daily performance of Dow Jones U.S. Basic Materials Index (the Index). The Index measures the performance of the basic materials industry of the United States equity market. The Fund invests in derivatives as a substitute for directly shorting stocks in order to gain inverse exposure to the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. The Fund also invests in short-term cash instruments that have terms to maturity of less than 397 days and exhibit credit profiles. ProShare Advisors LLC is the investment advisor of the Fund.

Viridian Therapeutics stock logo

Viridian Therapeutics NASDAQ:VRDN

$15.89 +0.22 (+1.40%)
Closing price 07/7/2025 04:00 PM Eastern
Extended Trading
$15.90 +0.00 (+0.03%)
As of 07/7/2025 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.